





Drug Delivery Systems

Ophthalmic

Transdermal

Parenteral

Intranasal



*Integral BioSystems' Archive
2013
Photo: Biodegradable PLG
Microspheres with an
Encapsulated Small Molecule
Drug for Sustained Release*

APRIL, 2014

Integral BioSystems CEO/CTO Dr. Shikha Barman Named "One of the 20 Women to Watch in 2014" by Mass High Tech

Boston Area Specialty Pharmaceutical Formulation Development Firm Integral BioSystems LLC Founder and CEO/CTO Dr. Shikha Barman to be feted as "One of the 20 Women to Watch in 2014" by Mass High Tech.

Dr. Shikha Barman, Chief Executive Officer and Chief Technology Officer of the startup Boston-area specialty pharmaceutical formulation development firm Integral BioSystems LLC, will be awarded the prestigious title of "One of the 20 Women to Watch in 2014" by Mass High Tech on May 8, 2014 at the Sheraton Boston Hotel. The award acknowledges her achievements as both a scientist and businesswoman in the Boston area as the entrepreneurial head of a cutting-edge drug development firm producing state-of-the-art microparticulate and nanoparticulate-based drug dosage forms, both under contract for third parties as well as for her firm's own products, OcuSurf™ and EySite™. OcuSurf™ is Integral BioSystems' novel, front-of-the-eye platform OcuSurf™ designed to enhance the persistence and bioavailability of ophthalmic formulations, while EySite™ offers a new approach to back-of-the-eye treatments to minimize their negative effects.

Responsible for both the business direction and technical guidance of the firm, Dr. Barman has approximately 20 years of work experience in the pharmaceutical and biotech industries in areas of drug delivery, pharmaceutical development and tissue engineering. Her interests have always been entrepreneurial, selecting the start-up venture over established companies, choosing to accept high risk in exchange for exponential professional growth usually experienced in innovative product development.

Under Dr. Barman's guidance, Integral BioSystems has developed numerous dosage forms for ophthalmic, oral, sublingual, intranasal, IV and transdermal routes, always taking a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.